Press Releases

NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)

THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON TUESDAY 19 MARCH 2019, AT 14.00 P.M., AT THE OFFICES OF THE COMPANY AT VALLONGATAN 1...

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 18 April 2018 issued a convertible loan with a total nominal amount of MSEK 26. In total circa MSEK 7 of the convertib...

Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019

The proposition on a new board of directors in Oasmia presented by Arwidsro Investment AB and Per Arwidsson (jointly “Arwidsro”) only a short period before the planned general meeting does not com...

Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) hereby announces that the board of directors of the Company has resolved to cancel the extraordinary general meeting which was to be...

European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information

Efficacy data from sub-group analysis for Apealea show significant advantage with regards to progression free survival in patients with first relapse

Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting

In 2017 and 2018, Oasmia has had a number of successful developments. Oasmia is currently in a phase where it has positive momentum with many ongoing activities.

NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)

THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON FRIDAY 25 JANUARY 2019, AT 14.00 P.M., AT THE OFFICES OF THE COMPANY AT VALLONGATAN ...

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 29 November 2017 and on 7 September 2018, issued convertible loans with total nominal amount of MSEK 28 and MSEK 35.2 ...

Oasmia Pharmaceutical AB (publ)

Interim report for the period May – October 2018

Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®

Oasmia Pharmaceutical AB (Nasdaq: OASM) today announce that the company has signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea. Technology a...